Results 81 to 90 of about 2,224,846 (160)

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP) [PDF]

, 2017
Q2Q1Artículo original513-523Background Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients ...
Martin, Claudio, Mauricio Cuello, Corrales Rodriguez, Luis, Zatarain-Barrón, Zyanya Lucia, Andrés F. Cardona, Hernán Carranza, Otero, Jorge, Vargas Baez, Carlos Alberto, Wills, Beatriz, Karachaliou, Niki, Noemí Reguart, Carranza Isaza, Hernan, Carlos Ortiz, Leonardo Rojas, Arrieta, Oscar, Cardona-Mendoza, Andrés Felipe, Archila, Pilar, Ortiz, Carlos, Archila Gomez, Maria del Pilar, Zatarain, Lucia, Cuello, Mauricio, Zapata, Martín Ignacio, Beatriz Wills, Rojas Puentes, Luis Leonardo, Carlos Vargas, Rojas Puentes, Leonardo, Martín Ignacio Zapata, Niki Karachaliou, Corrales, Luis, Jorge Otero, Oscar Arrieta, Claudio Martín, Pilar Archila, Reguart, Noemí, Zyanya Lucia Zatarain-Barrón, null null, Pino, Luis, Rosell, Rafael, Pino, Luis E., Luis Corrales, Cardona, Andrés Felipe, Rafael Rosell, Otero Bernal, Jorge Miguel, Luis E. Pino   +43 more
core   +1 more source

PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway

Cell Death and Disease
Epidermal growth factor receptor (EGFR)-targeted drugs (erlotinib, etc.) are used to treat multiple types of tumours. EGFR is highly expressed in most triple-negative breast cancer (TNBC) patients.
Yuanzhen Ma, Zhiyu Fang, Hongning Zhang, Yijun Qi, Yuke Mao, Junfang Zheng   +5 more
doaj   +1 more source

LncRNA MALAT-1 modulates EGFR-TKI resistance in lung adenocarcinoma cells by downregulating miR-125

Discover Oncology
Molecular targeted therapy resistance remains a major challenge in treating lung adenocarcinoma (LUAD). The resistance of Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitor ...
Jie Luo, Qiaoya Ren, Xiaoxi Liu, Qian Zheng, Ling Yang, Mi Meng, Hu Ma, Sisi He   +7 more
doaj   +1 more source

pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance

Acta Biochimica et Biophysica Sinica
EGFR protein trafficking is critical for regulating multiple biological processes, including cell growth and survival. However, how EGFR protein homeostasis is maintained remains unclear.
Ao Juan, Fei Junjie, Wang Guoqiang, Zhang Wenhua, Yu Shuhan, Guo Rongtian, Niu Mengmeng, Chen Hu, Cao Yang, Xiao Zhi-Xiong Jim, Yi Yong   +10 more
doaj   +1 more source

Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future

, 2010
Antimicrobial resistance among clinically important bacteria is widely acknowledged as a major global public health threat. A decade ago, several supranational surveillance initiatives were introduced. Few of them are still ongoing, and only one features
CORNAGLIA, Giuseppe, Giske CG, European Study Group on Antimicrobial Resistance Surveillance   +2 more
core   +1 more source

Abstract B47: Modeling epithelial plasticity-induced erlotinib resistance in non-small cell lung cancer

, 2018
Background: Advanced non-small lung cancer (NSCLC) patients with EGFR mutations initially respond to treatment with the EGFR-targeted tyrosine kinase inhibitors (TKIs) such as erlotinib, but will invariably acquire resistance with progression of disease ...
Zachary Yochum, Phuoc Tran, Charles Rudin, Katriana Nugent, Timothy Burns, Jessica Cades, Hailun Wang   +6 more
core   +1 more source

MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells

, 2017
Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several mechanisms implicated in resistance have been identified, but the existence of
J Vad-Nielsen, K R Jakobsen, C Demuth, B S Sorensen, A L Nielsen, A T Madsen, D Hussmann   +6 more
core   +1 more source

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines [PDF]

, 2015
PurposeAcquired resistance to erlotinib in patients with EGFR-mutant non-small cell lung cancer can result from aberrant activation of alternative receptor tyrosine kinases, such as the HGF-driven c-MET receptor. We sought to determine whether inhibition
Primo N. Lara, Lara, Primo N, David R. Gandara, Danielle C. Chinn, Gandara, David R, Chinn, Danielle C, William S. Holland, Philip C. Mack, Holland, William S, Mack, Philip C   +9 more
core   +1 more source

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells [PDF]

, 2011
Background:The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer.
F Solca, Solca, F, D Mackintosh, Guertler, U, Modjtahedi, H, Mackintosh, D, A G Dalgleish, Seddon, AM, Dalgleish, AG, N Ioannou, A M Seddon, U Guertler, Ioannou, N, Dalgleish, A G, H Modjtahedi, Seddon, A M   +15 more
core   +1 more source

A monoterpenoid dihydrochalcone derivative isolated from Conamomum rubidum sensitizes erlotinib-mediated lung cancer cell death by suppressing STAT3/Bcl-2 signaling

Medicine in Drug Discovery
Background: Resistance to erlotinib remains a major challenge in the treatment of non-small cell lung cancer (NSCLC), often driven by persistent activation of STAT3-mediated pro-survival signaling.
Iksen Iksen, Chayaporn Jitsayreerat, Chavisa Klanbunchum, Hien Minh Nguyen, Hanh Nhu Thi Hoang, Duc Viet Ho, Varisa Pongrakhananon   +6 more
doaj   +1 more source